2022
Dasiglucagon demonstrates reduced costs in the treatment of severe hypoglycemia in a budget impact model
Hinahara J, Weinzimer SA, Bromley ER, Goss TF, Kendall DM, Hammer M. Dasiglucagon demonstrates reduced costs in the treatment of severe hypoglycemia in a budget impact model. Journal Of Managed Care & Specialty Pharmacy 2022, 28: 10.18553/jmcp.2022.28.4.461. PMID: 35332789, PMCID: PMC10373001, DOI: 10.18553/jmcp.2022.28.4.461.Peer-Reviewed Original ResearchConceptsBudget impact modelHealth care resource utilizationSevere hypoglycemiaSH eventsGlucagon treatmentNasal glucagonUS commercial health planLower total health care costsSuccessful administrationTotal direct medical costsTotal health care costsPlasma glucose recoveryEmergency department visitsSevere hypoglycemic eventsInitial treatment successDirect medical costsCommercial health plansType 2 diabetesHealth care costsHealth economic modelEmergency medical servicesNative glucagonGlucagon analogsInjectable glucagonPrompt administration
2021
51-LB: Emotional Impact of Hypoglycemia and Use of Glucagon: Perspectives of People with T1D
HUGHES A, CHAPMAN K, BISPHAM J, HEYDARIAN N, DIMSITS J, WEINZIMER S, WOLF W. 51-LB: Emotional Impact of Hypoglycemia and Use of Glucagon: Perspectives of People with T1D. Diabetes 2021, 70 DOI: 10.2337/db21-51-lb.Peer-Reviewed Original ResearchSevere hypoglycemiaGlucagon useMini-dose glucagonUse of glucagonSevere hypoglycemic eventsEase of administrationOvernight hypoglycemiaGlycemic targetsHypoglycemia unawarenessHypoglycemic eventsPrescription costsSleep disruptorsTreatment decisionsNasal administrationHypoglycemiaDiabetes managementFocus groupsGlucagon actionGlucagon treatmentGlucagonEmotional impactAverage durationT1DPerspectives of peopleSpeakers bureau
2018
Predictive Low-Glucose Suspend Reduces Hypoglycemia in Adults, Adolescents, and Children With Type 1 Diabetes in an At-Home Randomized Crossover Study: Results of the PROLOG Trial
Forlenza GP, Li Z, Buckingham BA, Pinsker JE, Cengiz E, Wadwa RP, Ekhlaspour L, Church MM, Weinzimer SA, Jost E, Marcal T, Andre C, Carria L, Swanson V, Lum JW, Kollman C, Woodall W, Beck RW. Predictive Low-Glucose Suspend Reduces Hypoglycemia in Adults, Adolescents, and Children With Type 1 Diabetes in an At-Home Randomized Crossover Study: Results of the PROLOG Trial. Diabetes Care 2018, 41: dc180771. PMID: 30089663, DOI: 10.2337/dc18-0771.Peer-Reviewed Original ResearchConceptsType 1 diabetesSAP armPredictive low glucose suspendSensor-augmented pump therapyNew insulin delivery systemsRandomized Crossover StudySevere hypoglycemic eventsGlucose concentrationMin/dayMean glucose concentrationLow glucose suspendBasal-IQRebound hyperglycemiaSlim X2Glycemic controlPrimary outcomeCrossover studyMedian timeCrossover trialHypoglycemic eventsPump therapyInsulin delivery systemsPercentage of timeHypoglycemiaDiabetes
2009
The Effect of Continuous Glucose Monitoring in Well-Controlled Type 1 Diabetes
Beck R, Hirsch I, Laffel L, Tamborlane W, Bode B, Buckingham B, Chase P, Clemons R, Fiallo-Scharer R, Fox L, Gilliam L, Huang E, Kollman C, Kowalski A, Lawrence J, Lee J, Mauras N, O'Grady M, Ruedy K, Tansey M, Tsalikian E, Weinzimer S, Wilson D, Wolpert H, Wysocki T, Xing D. The Effect of Continuous Glucose Monitoring in Well-Controlled Type 1 Diabetes. Diabetes Care 2009, 32: 1378-1383. PMID: 19429875, PMCID: PMC2713649, DOI: 10.2337/dc09-0108.Peer-Reviewed Original ResearchConceptsType 1 diabetesContinuous glucose monitoringSevere hypoglycemic eventsCGM groupControl groupHypoglycemic eventsGlucose monitoringGlucose levelsSignificant treatment group differencesMain study outcomeManagement of adultsTreatment group differencesMin/dayStandard glucose monitoringMean A1CA1c levelsMedian timeOutcome measuresA1CBiochemical hypoglycemiaMost outcomesType 1Hypoglycemia dataStudy outcomesDiabetes